Rossari Biotech Limited

BSE: 543213 NSE: ROSSARI
Rossari Biotech Limited - chemicals and materials in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24100MH2009PLC194818 Incorporated 10 August 2009 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: ROSSARI · BSE: 543213 Public Limited Company chemicals and materials
Data last updated
Market Cap
₹2,518 Cr
ROSSARI · NSE
Share Price
₹437.50
-3.77% today
Revenue
₹2,396 Cr
FY 2025-26 · +15.2% YoY
EBITDA
₹286 Cr
Margin 11.9%
Net Profit
₹136 Cr
FY 2025-26 · -0.6% YoY
P/E (TTM)
16.7x
P/B 1.9x
ROE
11.8%
ROCE 14.5%
Debt / Equity
0.26
Interest cover 13.8x

About Rossari Biotech Limited

Data last updated:

Rossari Biotech Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the specialty chemicals segment of the chemicals and materials sector. It was incorporated on 10 August 2009 and has been in existence for over 17 years.

Its director Edward Menezes and family are #1,482 on the Hurun India Rich List 2026. Its director Sunil Chari and family are #1,482 on the Hurun India Rich List 2026.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24100MH2009PLC194818. Its GSTIN is 26AAECR4325G1ZJ (Dadra and Nagar Haveli and Daman and Diu). The company holds 3 GST registrations, of which 2 are active. Its shares are listed on BSE: 543213 and NSE: ROSSARI.

The company has an authorised share capital of ₹12 Cr and a paid-up capital of ₹11.08 Cr. It is led by directors including Sunil Srinivasan Chari (Managing Director) and Edward Walter Menezes (Whole-Time Director).

Its last annual general meeting (AGM) was held on 20 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹2,396.37 Cr, a growth of 15.2% compared to the previous year. For the same year it recorded a net profit of ₹135.6 Cr (net margin 5.7%) and EBITDA of ₹285.91 Cr (EBITDA margin 11.9%). The net worth stands at ₹1,333.35 Cr (up 12.5% YoY). Total assets are valued at ₹1,777.55 Cr (up 26.2% YoY).

The company has about 459 employees on its provident fund (EPFO) records. Its group structure includes 5 subsidiaries.

The company is associated with 2 brands: Rossari Biotech and Unitop Chemicals. As per MCA filings, the company has open charges of ₹279.43 Cr and satisfied charges of ₹110.54 Cr on record. Court records list 22 cases involving the company, including 16 filed by the company and 3 filed against it; 15 cases are pending. The company has 13 deals on record (8 market trades, 2 funding rounds, 2 secondary share transfers), with disclosed funding of ₹119.5 Cr; the latest was in April 2026. Its 10 peer companies in the Chemicals industry (Specialty Chemicals) are compared by revenue, 5 larger and 5 smaller; the largest is Aarti Drugs Limited with revenue of ₹2,403.39 Cr. The company has 58 MSME Form 1 returns on record between 2018 and 2024, listing 15,896 overdue payments to 800 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rossari.com.

Company Details of Rossari Biotech Limited
CIN L24100MH2009PLC194818
Registration Number 194818
Incorporation Date 10 August 2009
ROC Mumbai
Listing Status Listed (BSE: 543213, NSE: ROSSARI)
Company Status Active
Date of Last AGM 20 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN History of Rossari Biotech Limited

Rossari Biotech has one previous CIN (Corporate Identification Number): U24100MH2009PLC194818. The current CIN is L24100MH2009PLC194818, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24100MH2009PLC194818Current
U24100MH2009PLC194818Previous
Key People
Sunil Srinivasan Chari Managing Director Edward Walter Menezes Whole-Time Director Aseem Dhru Director

Recognitions & Rankings of Rossari Biotech

Hurun India 500 2021 edition
Rank#405
Valuation
₹7,520 Cr
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    rossari.com
  • Social Media
  • Registered Address
    Rossari House Golden Oak Lbs Marg Surya Nagar, Opp. Mahindra Showroom Vikhroli (West), Mumbai, Maharashtra, India – 400079
  • Industry
    Chemicals and Materials, Specialty Chemicals
Comprehensive company report
Rossari Biotech Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full Rossari Biotech Limited report

Financials, compliance, directors, charges, ownership and filings for Rossari Biotech Limited in one report.

Financials from 2015 Directors & ownership Charges & compliance

Associated Brands with Rossari Biotech Limited

Rossari Biotech operates two associated brands: Rossari Biotech and Unitop Chemicals. Each brand links to its own profile.

BrandDescriptionWebsite
Rossari Biotech
Manufacturer of textile and specialty chemicals for diverse industries and animal health nutrition productsrossari.com
Unitop Chemicals
Surfactants and emulsifiers are manufactured for industrial applications.unitopchemicals.com

Business Activity of Rossari Biotech Limited

The main business activity of Rossari Biotech is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Financials of Rossari Biotech Limited FY 2025-26 filings available

Rossari Biotech Limited reported revenue of ₹2,396.37 Cr (up 15.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,396 Cr
+15.2% YoY
EBITDA
₹286 Cr
+7.9% YoY
Profit After Tax
₹136 Cr
-0.6% YoY
Net Worth
₹1,333 Cr
+12.5% YoY
Total Assets
₹1,778 Cr
+26.2% YoY
Total Debt
₹436 Cr
+100.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,3962,0801,8311,6561,483709600
Revenue growth+15.2%+13.6%+10.6%+11.7%+109.1%+18.2%-
EBITDA286265250223183124105
EBITDA margin+11.9%+12.7%+13.6%+13.5%+12.4%+17.4%+17.4%
Profit before tax20318517814413610787.83
Net profit13613612910797.2379.8865.30
Net profit margin+5.7%+6.6%+7.1%+6.5%+6.6%+11.3%+10.9%
EPS (₹)26.9424.6323.6619.4517.7415.4512.86
Balance sheet
Total assets1,7781,4091,170999902410355
Net worth1,3331,1851,048915805409287
Total debt43621811973.938.430.0066.93
Cash & bank92.2157.1630.2112452.3588.26127
Net working capital733544456385312205197
Cash flow
Cash from operations65.0713743.2615229.3647.7756.83
Cash from investing(220)(183)(103)(181)(299)(37.18)(190)
Cash from financing18664.9016.1960.86292(24.59)157
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue697685582586544580513498
Revenue growth (YoY)+28.2%+18.2%+13.5%+17.6%+11.0%---
Other income3.6419.580.912.071.721.940.881.01
EBITDA80.6277.2568.8771.9367.8669.4964.7665.94
EBITDA margin+11.6%+11.3%+11.8%+12.3%+12.5%+12.0%+12.6%+13.2%
Depreciation25.6223.5319.6118.2317.7518.2218.3215.16
Interest10.989.067.676.095.735.504.943.68
Profit before tax47.6664.2442.5049.6846.1047.7142.3848.11
Tax12.5718.289.7312.7912.5113.2610.6712.78
Net profit35.0945.9632.7736.8933.5934.4531.7135.33
EPS (₹)6.338.295.916.656.066.215.726.38
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,7521,4321,2039751,073690600
Revenue growth+22.4%+19.0%+23.4%-9.1%+55.4%+15.1%-
EBITDA208186161123123121105
EBITDA margin+11.9%+13.0%+13.4%+12.6%+11.5%+17.6%+17.5%
Profit before tax19115513495.6410710688.11
Net profit12811497.4670.9678.0478.7765.58
Net profit margin+7.3%+7.9%+8.1%+7.3%+7.3%+11.4%+10.9%
EPS (₹)25.7920.7218.0412.9414.4415.2312.91
Balance sheet
Total assets1,3681,1301,030925786405352
Net worth1,2181,077960859785404283
Total debt14449.6968.0264.910.000.0066.93
Cash & bank51.8516.0225.6780.2734.8185.98127
Net working capital472331278249219201196
Cash flow
Cash from operations58.7392.2073.9211333.1252.0955.75
Cash from investing(102)(69.57)(69.78)(160)(318)(37.00)(187)
Cash from financing79.13(32.27)(22.09)61.21297(29.45)155
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue482516451420366427368336
Revenue growth (YoY)+31.9%+21.0%+22.4%+24.9%+21.6%---
Other income2.1922.731.141.401.742.401.011.08
Total expenses426453400369322374318292
EBITDA56.4263.6050.3850.4143.9552.2049.9644.27
EBITDA margin+11.7%+12.3%+11.2%+12.0%+12.0%+12.2%+13.6%+13.2%
Depreciation8.348.977.477.347.157.667.436.54
Interest3.843.813.952.493.093.082.281.90
Profit before tax46.4373.5540.1041.9835.4543.8641.2636.91
Tax12.1618.829.4710.739.2111.4910.639.50

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 19 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue697685582586544580513498
Revenue growth (YoY)+28.2%+18.2%+13.5%+17.6%+11.0%---
Other income3.6419.580.912.071.721.940.881.01
EBITDA80.6277.2568.8771.9367.8669.4964.7665.94
EBITDA margin+11.6%+11.3%+11.8%+12.3%+12.5%+12.0%+12.6%+13.2%
Depreciation25.6223.5319.6118.2317.7518.2218.3215.16
Interest10.989.067.676.095.735.504.943.68
Profit before tax47.6664.2442.5049.6846.1047.7142.3848.11
Tax12.5718.289.7312.7912.5113.2610.6712.78
Net profit35.0945.9632.7736.8933.5934.4531.7135.33
EPS (₹)6.338.295.916.656.066.215.726.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,3962,0801,8311,6561,483709600
Revenue growth+15.2%+13.6%+10.6%+11.7%+109.1%+18.2%-
Other income24.284.997.626.4413.549.123.72
Total expenses2,1101,8151,5811,4331,300586496
Employee cost15513210398.6267.9341.9837.21
EBITDA286265250223183124105
EBITDA margin+11.9%+12.7%+13.6%+13.5%+12.4%+17.4%+17.4%
Depreciation79.1267.0760.3962.9348.0622.8316.85
Interest28.5417.8119.3722.3212.662.993.56
Profit before tax20318517814413610787.83
Tax53.3048.8146.9336.9638.5826.7922.58
Net profit13613612910797.2379.8865.30
Net profit margin+5.7%+6.6%+7.1%+6.5%+6.6%+11.3%+10.9%
EPS (₹)26.9424.6323.6619.4517.7415.4512.86
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.0811.0711.0511.0311.0110.3910.15
Reserves & surplus1,3221,1741,037904794398277
Shareholders' funds (net worth)1,3331,1851,048915805409287
Minority interest0.000.000.000.000.000.000.00
Secured loans40818810663.950.000.0041.82
Unsecured loans27.9530.0312.979.988.430.0025.11
Total debt43621811973.938.430.0066.93
Total liabilities1,7781,4091,170999902410355
Assets
Gross block1,133878791743704234122
Net block78459857858560718193.54
Capital work in progress17314047.2116.081.340.3221.75
Investments62.2983.8062.8651.1735.920.0017.91
Inventories40535528218819095.3558.17
Sundry debtors55747442535430514494.14
Cash & bank balances92.2157.1630.2112452.3588.26127
Loans & advances14797.8768.3328.1450.6127.0333.06
Total current assets1,201985806694598355313
Total current liabilities468441350310286150116
Net working capital733544456385312205197
Total assets1,7781,4091,170999902410355
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash44.2025.1769.2037.4815.2129.215.74
Net cash from operating activities65.0713743.2615229.3647.7756.83
Net cash from investing activities(220)(183)(103)(181)(299)(37.18)(190)
Net cash from financing activities18664.9016.1960.86292(24.59)157
Net change in cash31.1119.03(44.03)31.7222.27(14.00)23.47
Closing cash92.2157.1630.2112452.3588.26127
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+15.2%+13.6%+10.6%+11.7%+109.1%+18.2%-
EBITDA growth+7.9%+6.1%+12.0%+21.6%+48.5%+18.2%-
PBT growth+9.4%+4.3%+23.2%+5.8%+27.6%+21.6%+38.6%
Net income growth-0.6%+5.4%+20.9%+10.1%+21.7%+22.3%-
Revenue CAGR (3Y)+13.1%+11.9%+37.2%+40.3%+42.2%--
EBITDA CAGR (3Y)+8.6%+13.1%+26.5%+28.7%+33.2%--
Profitability & leverage
Net income margin+6.2%+6.6%+7.1%+6.5%+6.6%+11.3%+10.9%
Return on capital employed+14.5%+15.7%+18.2%+17.5%+22.7%+28.7%+37.4%
Return on net worth+11.9%+12.2%+13.3%+12.5%+16.1%+23.0%+31.8%
Debt / equity0.260.150.100.050.010.100.18
Long-term debt / equity0.090.070.040.020.000.050.08
Interest cover13.808.9910.2313.949.352.974.06
Efficiency & per share
Fixed asset turnover2.382.492.392.293.163.985.75
Inventory turnover6.316.537.788.7510.409.2410.61
Debtors turnover4.644.624.705.036.615.966.67
EPS (₹)26.9424.6323.6619.4517.7415.4512.86
Dividend per share (₹)0.500.500.500.500.500.500.50
Book value per share (₹)240.74214.12189.65165.93146.2578.7256.48
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue482516451420366427368336
Revenue growth (YoY)+31.9%+21.0%+22.4%+24.9%+21.6%---
Other income2.1922.731.141.401.742.401.011.08
Total expenses426453400369322374318292
EBITDA56.4263.6050.3850.4143.9552.2049.9644.27
EBITDA margin+11.7%+12.3%+11.2%+12.0%+12.0%+12.2%+13.6%+13.2%
Depreciation8.348.977.477.347.157.667.436.54
Interest3.843.813.952.493.093.082.281.90
Profit before tax46.4373.5540.1041.9835.4543.8641.2636.91
Tax12.1618.829.4710.739.2111.4910.639.50
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,7521,4321,2039751,073690600
Revenue growth+22.4%+19.0%+23.4%-9.1%+55.4%+15.1%-
Other income27.015.746.773.6012.709.723.63
Total expenses1,5441,2451,042853950569495
Employee cost69.4660.0151.4657.3543.5336.6637.13
EBITDA208186161123123121105
EBITDA margin+11.9%+13.0%+13.4%+12.6%+11.5%+17.6%+17.5%
Depreciation30.9327.6924.1925.9826.2722.0716.85
Interest13.359.589.704.622.552.993.68
Profit before tax19115513495.6410710688.11
Tax48.2339.9634.4924.2627.2126.9022.58
Net profit12811497.4670.9678.0478.7765.58
Net profit margin+7.3%+7.9%+8.1%+7.3%+7.3%+11.4%+10.9%
EPS (₹)25.7920.7218.0412.9414.4415.2312.91
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital11.0811.0711.0511.0311.0110.3910.15
Reserves & surplus1,2071,066949848774394273
Shareholders' funds (net worth)1,2181,077960859785404283
Secured loans12730.1455.0554.930.000.0035.90
Unsecured loans17.7219.5512.979.980.000.0031.03
Total debt14449.6968.0264.910.000.0066.93
Total liabilities1,3681,1301,030925786405352
Assets
Gross block388323283256251220122
Net block21817916715717717193.54
Capital work in progress10534.0924.6013.680.840.3221.75
Investments5485385284933819.2515.21
Inventories18017915111310788.5258.17
Sundry debtors51837530224418113793.81
Cash & bank balances51.8516.0225.6780.2734.8185.98127
Loans & advances11882.2150.5012.4535.8527.6932.96
Total current assets868652529449359340312
Total current liabilities396321251200140139116
Net working capital472331278249219201196
Total assets1,3681,1301,030925786405352
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.9122.5540.5026.7414.8329.195.73
Net cash from operating activities58.7392.2073.9211333.1252.0955.75
Net cash from investing activities(102)(69.57)(69.78)(160)(318)(37.00)(187)
Net cash from financing activities79.13(32.27)(22.09)61.21297(29.45)155
Net change in cash35.74(9.64)(17.95)13.7611.91(14.36)23.46
Closing cash51.8516.0225.6780.2734.8185.98127
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+22.4%+19.0%+23.4%-9.1%+55.4%+15.1%-
EBITDA growth+11.9%+15.5%+31.5%-0.1%+1.2%+15.5%-
PBT growth+23.5%+15.3%+40.3%-10.3%+0.6%+20.3%+38.9%
Net income growth+12.5%+16.5%+37.3%-9.1%-0.9%+20.1%-
Revenue CAGR (3Y)+21.6%+10.1%+20.3%+17.6%+27.6%+33.3%+37.0%
EBITDA CAGR (3Y)+19.3%+14.9%+10.0%+5.3%+16.5%+39.2%+62.4%
Profitability & leverage
Net income margin+8.2%+8.0%+8.3%+7.3%+7.4%+11.5%+10.9%
Return on capital employed+14.7%+15.2%+14.7%+11.7%+18.3%+28.8%+38.0%
Return on net worth+11.1%+11.3%+11.0%+8.7%+13.4%+23.0%+32.5%
Debt / equity0.080.060.070.040.000.100.19
Long-term debt / equity0.020.030.040.020.000.050.09
Interest cover7.526.047.084.782.643.014.17
Efficiency & per share
Fixed asset turnover4.934.724.463.844.554.035.75
Inventory turnover9.778.689.118.8510.959.4110.61
Debtors turnover3.924.234.414.596.745.976.69
EPS (₹)25.7920.7218.0412.9414.4415.2312.91
Dividend per share (₹)0.500.500.500.500.500.500.50
Book value per share (₹)220.00194.56173.83155.69142.5077.8855.85
Want more history and ratios?
You're viewing the latest exchange-filed financials for Rossari Biotech Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Board of Directors of Rossari Biotech Limited

Rossari Biotech has 6 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Aseem Dhru
Also directs: Safari Industries (India) Limited, SBFC Finance Limited, SBFC Home Finance Private Limited
Director12 Nov 20196 Years 11 MonthsCurrent
Sunil Srinivasan Chari
Also directs: Sunjyot Properties LLP, Rossari Biotech (India) Private Limited, Unitop Chemicals Private Limited and 5 more
Managing Director26 Sep 20197 Years 0 MonthsCurrent
Edward Walter Menezes
Also directs: Rossari Biotech (India) Private Limited, Unitop Chemicals Private Limited, Rossari Consumer Products Private Limited and 5 more
Whole-Time Director10 Aug 200917 Years 2 MonthsCurrent
Gurudas Vishwas Aras
Also directs: Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Romakk Chemicals Private Limited and 2 more
Director19 Oct 20242 Years 0 MonthsCurrent
Esha Padmanabhan Achan
Also directs: Man Industries (India) Limited, Meganet Technologies Global Limited
Director21 Oct 20232 Years 11 MonthsCurrent
Udeypaul Singh Gill
Also directs: Vardhman Textiles Limited, Banswara Syntex Ltd, Nirvrt Consultancy Private Limited
Director28 Apr 20260 Years 5 MonthsCurrent
View all directors

Peer Comparison of Rossari Biotech Limited

Rossari Biotech Limited is compared with the companies closest to it by revenue in the Chemicals industry (Specialty Chemicals). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Aarti Drugs Limited Listed₹2,403.39 Cr (FY 2025)••••••••-5.0%••••Thane, Maharashtra, India
Rossari Biotech Limited this company₹2,396.37 Cr (FY 2026)••••••••15.2%••••Mumbai, Maharashtra, India
Fine Organic Industries Limited Listed₹2,366.75 Cr (FY 2025)••••••••8.0%••••Mumbai, Maharashtra, India
Vinati Organics Limited Listed₹2,292.48 Cr (FY 2025)••••••••18.0%••••Dist-Raigad, Maharashtra, India
Performance Chemiserve Limited₹2,185.27 Cr (FY 2025)••••••••73.0%••••Pune, Maharashtra, India
Iol Chemicals and Pharmaceuticals Limited Listed₹2,101.62 Cr (FY 2025)••••••••-3.0%••••Barnala, Punjab, India
Kutch Chemical Industries Limited₹1,985.16 Cr (FY 2024)••••••••-33.0%••••New Delhi, Delhi, India
Godavari Biorefineries Limited₹1,886.91 Cr (FY 2025)••••••••11.0%••••Mumbai, Maharashtra, India
Hikal Limited Listed₹1,864.8 Cr (FY 2025)••••••••4.0%••••Mumbai, Maharashtra, India
TGV Sraac Limited Listed₹1,763.22 Cr (FY 2025)••••••••13.0%••••Kurnool, Andhra Pradesh, India
Shree Ganesh Edibles Private Limited₹1,702.88 Cr (FY 2025)••••••••34.0%••••Khanna, Punjab, India

Peers are the five companies nearest above and the five nearest below Rossari Biotech by revenue in the Chemicals industry (Specialty Chemicals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details of Rossari Biotech Limited

Rossari Biotech Limited is audited by DELOITTE HASKINS & SELLS LLP for the financial year 2023.

NameStatusAppointment DateCessation Date
DELOITTE HASKINS & SELLS LLPLockedLockedLocked
Premium access

Complete auditor history

Appointment and cessation dates and past auditor changes are in the company report.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Shareholding Pattern of Rossari Biotech Limited

Shareholding for the quarter ended Sep 2026: promoters hold 68.10%, foreign institutional investors hold 2.00%, domestic institutional investors hold 14.70% and retail and other public shareholders hold 15.20%.

Promoters: 68.10%DII (Domestic Institutional): 14.70%FII (Foreign Institutional): 2.00%Retail & Others: 15.20%
Sep 2026
QUARTER
68.10% Promoters
14.70% DII (Domestic Institutional)
2.00% FII (Foreign Institutional)
15.20% Retail & Others
Promoter holding - history
Now 68.10% · Sep 2026High 68.20% · Dec 2025Low 68.10% · Sep 2026
67%67.8%68.5%69.3%70%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 68.20%Mar 2026: 68.20%Jun 2026: 68.20%Sep 2026: 68.10%68.20%68.10%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters68.10%68.20%68.20%68.20%
Public31.90%31.80%31.80%31.80%

Charges & Borrowings of Rossari Biotech Limited

Open charges
₹279.43 Cr
Satisfied charges
₹110.54 Cr
Breakdown by lending institutions
Hdfc Bank Limited₹81.62 Cr
Axis Bank Limited₹75.00 Cr
Citi Bank N.A.₹50.00 Cr
The Hongkong and Shanghai Banking Corporation Limited₹30.00 Cr
Standard Chartered Bank₹25.00 Cr
Others₹17.81 Cr
Latest charge details
DateLenderAmountStatus
05 Mar 2026Others₹1.68 CrOpen
05 Mar 2026Others₹61 LakhOpen
23 Dec 2025Others₹89.38 LakhOpen
18 Dec 2025Others₹1.03 CrOpen
06 Nov 2025Others₹89.5 LakhOpen

Total charge records: 26 View all charges

Deals & Funding of Rossari Biotech Limited

Rossari Biotech Limited has 13 deals on record (8 market trades, 2 funding rounds, 2 secondary share transfers), with disclosed funding of ₹119.5 Cr; the latest was in April 2026.

Total deals
13
Market trades
8
Funding rounds
2
Secondary share transfers
2
IPO
1
Disclosed funding
₹119.5 Cr

Deals on record (5 of 13)

WhenDealAmountParties
Sep 2020Market trade₹23.22 CrBuyer: Plutus Wealth Management LLP
Jul 2020Market trade₹20.14 CrBuyer: Two Roads Trading Private Limited
Seller: Two Roads Trading Private Limited
Jul 2020Market trade₹691.07 CrBuyer: Alphagrep Securities Private Limited , Genuine Stock Brokers Private Limited , Two Roads Trading Private Limited
Seller: Alphagrep Securities Private Limited , Genuine Stock Brokers Private Limited , Two Roads Trading Private Limited
Jul 2020Market trade₹44.39 CrBuyer: Millennium Stock Broking Private Limited
Seller: Millennium Stock Broking Private Limited
Jul 2020IPO₹496.25 CrInvestors: Abu Dhabi Investment Authority, Sundaram Mutual Fund, HDFC Mutual Fund
Seller: 2 individuals
Premium access

Full deal history

All 13 deals with amounts, valuations, instruments and every party are in the company report.

  • Every funding round and share transfer
  • Amounts and valuations
  • Investors, buyers and sellers
  • Instruments and deal dates

Verified entity values are shown only after access is granted.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays by Rossari Biotech Limited

Rossari Biotech Limited has 58 MSME Form 1 returns on record between 2018 and 2024, listing 15,896 overdue payments to 800 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 800)

SupplierAmount dueDue sinceReported on
Prince Multiplast Private Limited••••••••••••
Banas Resources LLP••••••••••••
an individual supplier••••••••••••
Pradeep Laminators Private Limited••••••••••••
Precise Healthcare Private Limited••••••••••••
Premium access

Full MSME payment history

Every supplier, amount and due date from all 58 MSME Form 1 returns is in the company report.

  • Every reported supplier due
  • Amounts and due dates
  • Reasons given in each return
  • Period-by-period history

Verified entity values are shown only after access is granted.

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance at Rossari Biotech Limited

Rossari Biotech Limited has a workforce of 459 employees as of Mar 22, 2024.

Employee count
459
Active EPFO establishments
2
Employee growth
-4.77%
Premium access

Employee and EPFO history

Monthly headcount, contribution history and filing status are in the company report.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

Group Structure of Rossari Biotech Limited

Rossari Biotech has 5 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

5
Subsidiary companies
Key Subsidiaries
Company NameCINShares Held
Unitop Chemicals Private LimitedU24110MH1980PTC022967-
Rossari Consumer Products Private LimitedU24110MH1999PTC121848-
Tristar Intermediates Private LimitedU24231GJ1997PTC032927-
Buzil Rossari Private LimitedU24297MH2013PTC251413-
Romakk Chemicals Private LimitedU24299MH2021PTC357112-

Showing major subsidiaries. Total: 5.

Recent Activity on Rossari Biotech Limited

Rossari Biotech Limited has 20 board changes on record since 2009: 14 appointments and 6 cessations. The latest: Udeypaul Singh Gill was appointed as Director on 28 Apr 2026.

AGM
Rossari Biotech Limited last Annual general meeting of members was held on 20 Jul 2026 as per latest MCA records.
Appointed
Udeypaul Singh Gill was appointed as Director.
Filing
Rossari Biotech Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with Others amounted to Rs. 1.68 Cr with Charge ID 101258026 was registered on 05 Mar 2026.
Charges
A charge with Others amounted to Rs. 0.61 Cr with Charge ID 101258017 was registered on 05 Mar 2026.
Charges
A charge with Others amounted to Rs. 0.89 Cr with Charge ID 101216710 was registered on 23 Dec 2025.
Charges
A charge with Others amounted to Rs. 1.03 Cr with Charge ID 101232888 was registered on 18 Dec 2025.
Charges
A charge with Others amounted to Rs. 0.90 Cr with Charge ID 101190280 was registered on 06 Nov 2025.
Charges
A charge with Others amounted to Rs. 1.20 Cr with Charge ID 101181094 was registered on 17 Oct 2025.
Charges
A charge registered on 12 Oct 2022 via Charge ID 100623997 with Citi Bank N.A. was fully satisfied on 15 Oct 2025.
Ceased
Sharabh Pachory ceased to be Director.
Appointed
Gurudas Vishwas Aras was appointed as Director.

60 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts for Rossari Biotech Limited

Premium access

Credit ratings, litigation, and regulatory alerts

Credit ratings, court records and regulatory alerts are in the company report.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Rossari Biotech Limited

Premium access

Corporate group structure

Parent, subsidiary, associate and joint venture records with holdings are in the company report.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

GST Compliance of Rossari Biotech Limited

Rossari Biotech has 3 GST registrations: 2 active and 1 cancelled or inactive.

Total GSTINs
3
Active
2
Cancelled / inactive
1
GSTINStateStatusRegistered on
26AAECR4325G1ZJDadra and Nagar Haveli and Daman and DiuActive01 Jul 2017
24AAECR4325G2ZMGujaratActive01 Apr 2018
Premium access

GST registrations and filing compliance

State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Rossari Biotech Limited

Premium access

MCA filings and documents

Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Related news about Rossari Biotech Limited

Rossari Biotech: Anticipates Achieving Debt-Free Status In The Coming Months.
19 Oct 2026 · Exchange Update

Frequently Asked Questions about Rossari Biotech Limited

Rossari Biotech is an active public limited company based in Mumbai, Maharashtra, India. The company works in specialty chemicals, within the chemicals and materials industry. It was incorporated on 10 August 2009 (17+ years old) and is registered under CIN L24100MH2009PLC194818. Listed on BSE: 543213 and NSE: ROSSARI.

Rossari Biotech reported revenue of ₹2,396.37 Cr for FY 2025-26 (up 15.2% YoY) based on consolidated financials.

Rossari Biotech has 6 current directors:

The GSTIN of Rossari Biotech is 26AAECR4325G1ZJ, registered in Dadra and Nagar Haveli and Daman and Diu. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 24AAECR4325G2ZM (Gujarat).

The CIN (Corporate Identification Number) of Rossari Biotech is L24100MH2009PLC194818. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Rossari Biotech is listed on both BSE (code: 543213) and NSE (symbol: ROSSARI).

Rossari Biotech has 22 court cases on record: 16 filed by the company and 3 filed against it. 15 are pending. Most are in the district courts.

Rossari Biotech was incorporated on 10 August 2009, making it 17+ years old. It is registered with the Registrar of Companies, Mumbai.

Rossari Biotech has 13 deals on record (8 market trades, 2 funding rounds, 2 secondary share transfers), with disclosed funding of ₹119.5 Cr; the latest was in April 2026.

The peers of Rossari Biotech by revenue are Aarti Drugs Limited, Fine Organic Industries Limited, Vinati Organics Limited, Performance Chemiserve Limited, Iol Chemicals and Pharmaceuticals Limited and 5 more, all in the Chemicals industry (Specialty Chemicals).

Udeypaul Singh Gill was appointed as Director on 28 Apr 2026. Sharabh Pachory ceased to be Director on 11 Nov 2024. Gurudas Vishwas Aras was appointed as Director on 19 Oct 2024. Rossari Biotech has 20 board changes on record in total.

Rossari Biotech has 58 MSME Form 1 returns on record between 2018 and 2024, listing 15,896 overdue payments to 800 micro and small suppliers. The latest return was filed on 01 May 2024.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available